Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 45

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 45
---
 sales of instruments was $33.0 million, of which approximately $22.1 million is expected to be recognized to revenue in the next 12 months, with the 

13

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

remainder thereafter. The contract liabilities of $33.0 million and $33.2 million as of September 30, 2025 and December 31, 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Deferred revenue recognized$4,134 $2,713 $15,038 $9,454 The following table represents revenue by source for the periods indicated (in thousands). Chromium products include the Company’s single cell products and spatial products include the Company’s Visium and Xenium products:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024InstrumentsChromium$4,927 $7,641 $16,567 $24,283 Spatial7,072 11,415 24,744 44,078 Total instruments revenue11,999 19,056 41,311 68,361 ConsumablesChromium92,519 96,536 262,416 274,571 Spatial35,373 29,668 103,017 85,330 Total consumables revenue127,892 126,204 365,433 359,901 Services8,128 6,299 24,255 17,292 Products and services revenue148,019 151,559 430,999 445,554 License and royalty revenue983 95 45,794 210 Total revenue$149,002 $151,654 $476,793 $445,764 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024AmericasUnited States(1)$77,246 $84,723 $267,555 $250,032 Americas (excluding United States)2,625